Monkeypox Could Easily Mutate To Resist Antiviral Treatment, FDA Says

By Jessica Karins / September 15, 2022 at 5:57 PM
FDA recommends providers be cautious in deciding to which patients with monkeypox they prescribe tecovirimat, or TPOXX, out of concern that the virus could easily evolve to resist the antiviral treatment with a small change to one protein. At a press briefing on the administration’s monkeypox response Thursday (Sept. 15), National Institute of Allergies and Infectious Diseases Director Anthony Fauci said an upcoming study on the monkeypox treatment tecovirimat will examine potential resistance to the drug, among other factors. The...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.